BlackRock’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $542M | Sell |
6,237,151
-60,183
| -1% | -$5.85M | 0.01% | 1047 |
|
|
2025
Q4 | $674M | Sell |
6,297,334
-4,881
| -0.1% | -$518K | 0.01% | 904 |
|
|
2025
Q3 | $636M | Buy |
6,302,215
+34,677
| +0.6% | +$3.22M | 0.01% | 928 |
|
|
2025
Q2 | $396M | Sell |
6,267,538
-587,217
| -9% | -$36M | 0.01% | 1203 |
|
|
2025
Q1 | $363M | Sell |
6,854,755
-95,960
| -1% | -$5.32M | 0.01% | 1228 |
|
|
2024
Q4 | $389M | Buy |
6,950,715
+61,457
| +0.9% | +$3.39M | 0.01% | 1242 |
|
|
2024
Q3 | $361M | Buy |
6,889,258
+147,335
| +2% | +$7.06M | 0.01% | 1300 |
|
|
2024
Q2 | $277M | Buy |
6,741,923
+212,277
| +3% | +$8.47M | 0.01% | 1404 |
|
|
2024
Q1 | $283M | Buy |
6,529,646
+177,896
| +3% | +$7.79M | 0.01% | 1416 |
|
|
2023
Q4 | $292M | Buy |
6,351,750
+151,868
| +2% | +$4.79M | 0.01% | 1386 |
|
|
2023
Q3 | $142M | Sell |
6,199,882
-65,123
| -1% | -$1.46M | ﹤0.01% | 1776 |
|
|
2023
Q2 | $103M | Buy |
6,265,005
+2,484,406
| +66% | +$44.8M | ﹤0.01% | 2030 |
|
|
2023
Q1 | $67.4M | Buy |
3,780,599
+56,885
| +2% | +$1.43M | ﹤0.01% | 2265 |
|
|
2022
Q4 | $108M | Buy |
3,723,714
+186,215
| +5% | +$4.79M | ﹤0.01% | 1932 |
|
|
2022
Q3 | $86.7M | Buy |
3,537,499
+2,359,924
| +200% | +$43.9M | ﹤0.01% | 2063 |
|
|
2022
Q2 | $4.89M | Sell |
1,177,575
-2,106,530
| -64% | -$11.5M | ﹤0.01% | 3828 |
|
|
2022
Q1 | $37.8M | Sell |
3,284,105
-43,956
| -1% | -$386K | ﹤0.01% | 2745 |
|
|
2021
Q4 | $33.2M | Sell |
3,328,061
-33,925
| -1% | -$381K | ﹤0.01% | 2956 |
|
|
2021
Q3 | $43.9M | Buy |
3,361,986
+26,325
| +0.8% | +$402K | ﹤0.01% | 2750 |
|
|
2021
Q2 | $65.3M | Buy |
3,335,661
+190,301
| +6% | +$3.95M | ﹤0.01% | 2522 |
|
|
2021
Q1 | $66.9M | Buy |
3,145,360
+414,254
| +15% | +$12M | ﹤0.01% | 2431 |
|
|
2020
Q4 | $81.2M | Buy |
2,731,106
+91,754
| +3% | +$2.33M | ﹤0.01% | 2200 |
|
|
2020
Q3 | $57.2M | Sell |
2,639,352
-156,489
| -6% | -$3.59M | ﹤0.01% | 2213 |
|
|
2020
Q2 | $62.3M | Buy |
2,795,841
+298,715
| +12% | +$5.82M | ﹤0.01% | 2126 |
|
|
2020
Q1 | $38M | Sell |
2,497,126
-57,640
| -2% | -$1.03M | ﹤0.01% | 2236 |
|
|
2019
Q4 | $58.7M | Buy |
2,554,766
+615,615
| +32% | +$13.7M | ﹤0.01% | 2259 |
|
|
2019
Q3 | $41.9M | Buy |
1,939,151
+31,093
| +2% | +$667K | ﹤0.01% | 2402 |
|
|
2019
Q2 | $42M | Buy |
1,908,058
+380,085
| +25% | +$9.6M | ﹤0.01% | 2427 |
|
|
2019
Q1 | $41.9M | Sell |
1,527,973
-26,733
| -2% | -$768K | ﹤0.01% | 2373 |
|
|
2018
Q4 | $41.8M | Buy |
1,554,706
+413,203
| +36% | +$11.4M | ﹤0.01% | 2342 |
|
|
2018
Q3 | $33.3M | Buy |
1,141,503
+393,834
| +53% | +$12.4M | ﹤0.01% | 2595 |
|
|
2018
Q2 | $23.4M | Buy |
747,669
+361,867
| +94% | +$9.89M | ﹤0.01% | 2768 |
|
|
2018
Q1 | $7.68M | Buy |
385,802
+25,731
| +7% | +$683K | ﹤0.01% | 3248 |
|
|
2017
Q4 | $10.5M | Buy |
+360,071
| New | +$9.52M | ﹤0.01% | 3122 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
BlackRock's RYTM Position: Q1 2026 in Review
BlackRock reduced its Rhythm Pharmaceuticals (RYTM) stake by 0.96% in Q1 2026, selling an estimated $5.85M and leaving 6,237,151 shares worth $542M. The position accounts for 0.01% of the portfolio, ranked #1047.
BlackRock first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $674M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- BlackRock held 6,237,151 shares of Rhythm Pharmaceuticals worth $542M as of Q1 2026.
- BlackRock sold 60,183 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $5.85M.
- Rhythm Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q1 2026, its #1047 holding.
- BlackRock first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- BlackRock's Rhythm Pharmaceuticals position peaked at $674M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.